7 unchanged sentences
Form of Common Stock Certificate.
−Removed: 2020 Incentive Award Plan.
−Removed: Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan.
−Removed: Form of Restricted Stock Award Agreement under the 2020 Incentive Award Plan.
−Removed: Form of Restricted Stock Unit Award Grant Notice under the 2020 Incentive Award Plan.
−Removed: 2020 Employee Stock Purchase Plan.
−Removed: Non-Employee Director Compensation Program.
−Removed: Form of Indemnification Agreement for directors and officers
−Removed: Amended and Restated Investors Rights Agreement dated October 9, 2020.
−Removed: Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934,
−Removed: as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934,
−Removed: as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Amended and Restated Employment Agreement, effective as of February 10, 2021, by and between the Company and Leonid Beigelman.
+Added: Amended and Restated Employment Agreement, effective as of February 10, 2021, by and between the Company and Lawrence M.
+Added: Employment Agreement by and between Aligos Therapeutics, Inc.
+Added: and Julian Symons, D.Phil., effective as of May 14, 2019
+Added: Form of Change in Control and Severance Agreement.
+Added: Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Executive Officer Pursuant to 18 U.S.C.
10 unchanged sentences
The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Aligos Therapeutics, Inc.
−Removed: under the Securities Act of 1933, as
−Removed: amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
−Removed: its behalf by the undersigned thereunto duly authorized.
+Added: under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ALIGOS THERAPEUTICS, INC.
−Removed: November 25, 2020
/s/ Lawrence Blatt
1 unchanged sentence
Chief Executive Officer
−Removed: November 25, 2020
/s/ Lesley Ann Calhoun
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.